Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review

@article{Gera2018DoesTT,
  title={Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review},
  author={Ritika Gera and Salim Tayeh and Hiba El Hage Chehade and Kefah Mokbel},
  journal={AntiCancer Research},
  year={2018},
  volume={38},
  pages={6615 - 6620}
}
Background/Aim: Hypoactive sexual desire disorder (HSDD) is hypothesised to manifest in postmenopausal women at onset of menopause due to decreased oestrogen levels. Transdermal testosterone is a potential treatment option. This systematic review explores the relationship between the incidence of breast cancer and transdermal testosterone use. Materials and Methods: Searches were conducted on the PubMed and Ovid databases. In Ovid, the advanced search function was used: ‘transdermal… 

Tables from this paper

Hormonal profile of menopausal women receiving androgen replacement therapy: a meta-analysis
TLDR
Whatever androgen formulation the authors choose in postmenopausal women, the end result is a rise in testosterone serum levels, however, DHEA regimen is also associated with an increased estrogenic availability, which might be crucial when choosing the best possible treatment for each patient individually.
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study
TLDR
Long term therapy with subcutaneous testosterone, or testosterone combined with anastrozole, did not increase the incidence of invasive breast cancer and Testosterone should be further investigated for hormone therapy and breast cancer prevention.
Hair chemicals may increase breast cancer risk: A meta-analysis of 210319 subjects from 14 studies
TLDR
Chemicals in hair dyes may play a role in breast carcinogenesis and increase breast cancer risk in women.
The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk?
TLDR
This review aims to elucidate whether androgens might influence the susceptibility for breast cancer, and the possibility to exploit the AR as a useful marker to predict the disease will be also evaluated.
Sexual Health in Menopause
TLDR
Although first-line therapeutic strategies for menopause-related sexual dysfunction aim at addressing modifiable factors, many hormonal and non-hormonal, local and systemic treatment options are currently available.
Risks of Testosterone for Postmenopausal Women.
The testosterone prescribing practice of BMS menopause specialists
TLDR
Ask menopause experts from around the UK to see if a consensus could be reached about good prescribing practice and the method and results as discussed below may be helpful in future recommendations and guidance.
Hair dye use and prostate cancer risk: A prospective analysis in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study cohort
TLDR
According to the International Agency for Research on Cancer, some hair dye chemicals are considered mutagenic and carcinogenic in humans, but no prospective analyses have been conducted.
...
1
2
...

References

SHOWING 1-10 OF 36 REFERENCES
Clinical review: Controversies regarding transdermal androgen therapy in postmenopausal women.
  • S. Basaria, A. Dobs
  • Medicine, Biology
    The Journal of clinical endocrinology and metabolism
  • 2006
TLDR
A short-term trial of transdermal testosterone therapy (once approved) in surgically menopausal (estrogenized) women with distressful sexual dysfunction is recommended and a short trial of oral methyltestosterone in deserving estrogenized women may be justified.
Androgens and breast cancer risk
  • P. Kenemans, M. J. van der Mooren
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2012
TLDR
The evidence available so far makes counselling women interested in testosterone supplementation for distressful low sexual desire, more of an art than science.
The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
TLDR
Surgically menopausal women receiving testosterone experience significant increases in total satisfying sexual activity vs. women receiving placebo, significant improvement in all domains of sexual function, and decreases in personal distress, with a favorable safety profile.
Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation
TLDR
The aim is to assess published studies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework for the quality of evidence regarding testosterone use as a short- and long-term therapy for HSDD with minimal side effects.
Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women.
TLDR
The transdermal testosterone patch is an effective treatment for hypoactive sexual desire disorder in surgically postmenopausal women receiving concomitant estrogen therapy and has a favorable safety profile.
The incidence of invasive breast cancer among women prescribed testosterone for low libido.
TLDR
Testosterone use was not associated with a significant increase in breast cancer risk, and the standardized incidence rate ratio (IRR) calculated using Australian age-specific incidence rates for 2005 was 1.35 (95% confidence interval 0.76-2.38).
The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy.
TLDR
TTP therapy over 52 wk appears to have no significant effect on digitally quantified absolute or percent dense mammographic area in postmenopausal women not using EPT.
Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
TLDR
In the Intimate SM 1 study, the testosterone patch improved sexual function and decreased distress in surgically menopausal women with HSDD and was well tolerated in this trial.
...
1
2
3
4
...